O. Deckard. Northern Michigan University.
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre quality 100 mg dipyridamole blood pressure psi. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta dipyridamole 100 mg line hypertension erectile dysfunction. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon- beta used for patients with relapsing-remitting multiple sclerosis. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Martinelli V, Gironi M, Rodegher M, Martino G, Comi G. Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon- beta treatment. Effect of 1-year treatment with interferon- beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b. Disease-modifying drugs for multiple sclerosis Page 91 of 120 Final Report Update 1 Drug Effectiveness Review Project 116. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? The incidence and significance of anti- natalizumab antibodies: results from AFFIRM and SENTINEL. Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). Journal of neuro-ophthalmology : the official journal of the North American Neuro- Ophthalmology Society. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double- blind, placebo-controlled trial.
Pegylated interferons for hepatitis C Page 38 of 65 Final Report Drug Effectiveness Review Project SUMMARY AND DISCUSSION Results of this evidence review are summarized in Table 13 dipyridamole 25mg otc hypertension zinc deficiency. Summary of the evidence by key question Key Question Quality of the Conclusion Evidence 1 discount 100 mg dipyridamole visa blood pressure kits for sale. What is the comparative Fair to poor All trials are efficacy studies. Evidence is insufficient to effectiveness of regimens of judge comparative efficacy. Head-to-head trial data are peginterferon alfa-2a plus ribavirin sparse (two trials), short-term (8 to 12 weeks), clinically versus peginterferon alfa-2b plus diverse, and had methodological flaws. There are also no clear differences in sustained biochemical response. Data on histologic outcomes and quality of life are sparse and there are no data on other outcomes such as cirrhosis, hepatocellular cancer, liver transplant, or functional status. How does duration of treatment Fair to poor Studies evaluating effects of dose and duration are of or dosing protocols (including limited value for evaluating comparative effectiveness of weight-based or maintenance dual therapy with pegylated interferon alfa-2a versus dosing or dosing of ribavirin) affect pegylated interferon alfa-2b because none directly estimates of comparative compared effects of duration or dose between the two effectiveness? Trials comparing different doses of pegylated interferon as part of dual therapy are only available for pegylated interferon alfa-2b. Trials directly comparing different durations of therapy are available for dual therapy with pegylated interferon alfa-2a and for dual therapy with pegylated interferon alfa-2b, but are characterized by substantial clinical diversity across trials in patient populations, dosing of drugs, and/or duration of therapy. What is the comparative Fair to poor Evidence is insufficient to judge comparative safety. Head- tolerability and safety of to-head trial data are extremely sparse (one short-term trial) peginterferon alfa-2a plus ribavirin and inadequate for judging comparative safety. Indirect versus peginterferon alfa-2b plus analysis shows no significant differences in rates of ribavirin for treatment of chronic withdrawal due to adverse events or other adverse events, hepatitis C virus infection? Observational studies were almost all non-comparative and provided no additional useful information on comparative safety. Pegylated interferons for hepatitis C Page 39 of 65 Final Report Drug Effectiveness Review Project Key Question Quality of the Conclusion Evidence 3. Does the comparative effectiveness or tolerability and safety of peginterferon alfa-2a plus ribavirin versus peginterferon alfa- 2b plus ribavirin vary in patient subgroups? Race, gender, age Poor No evidence on comparative effectiveness or safety based on demographics. Evidence from indirect analysis is insufficient to conclude that dual therapy with one pegylated interferon is superior to the other for infection with specific HCV genotypes. Severity of baseline disease Poor No trials evaluated comparative effectiveness or safety in patients with higher viral loads, more severe fibrosis or inflammation, or other markers of more severe baseline HCV disease. Obese patients Poor Subgroup analyses of three trials found dual therapy with pegylated interferon alfa-2a and alfa-2b less effective at achieving an SVR in patients over 75 to 80 kg, compared to those below 75 to 80 kg. No trials have evaluated comparative effectiveness or safety of weight-based versus standardized dosing of pegylated interferon as part of dual therapy in obese patients. Indirect analysis indicates no significant differences in rates of sustained virologic response in HIV co-infected patients, though interpretation of findings is limited by clinical diversity across trials and imprecise estimates of effects. Non-responders or relapsers Poor No comparative evidence. We found insufficient evidence to determine whether dual therapy with pegylated interferon alfa-2a differs from dual therapy with pegylated interferon alfa-2b in efficacy or safety. Evaluating comparative effectiveness and safety is very challenging at this time because the only data from head-to-head trials consist of short-term virologic outcomes. In addition, estimates from indirect analyses are imprecise and may not be reliable because of differences across trials in patient populations, dosing regimens for both pegylated interferon and ribavirin, comparator therapies (dual therapy with non-pegylated interferon alfa-2a or dual therapy with non-pegylated interferon alfa-2b), and other factors. Interestingly, when indirect analyses are limited to trials comparing dual therapy with pegylated interferon alfa-2a and dual therapy with pegylated interferon alfa-2b to the same common comparator (dual therapy with non-pegylated interferon alfa-2b), the point estimate for the likelihood of achieving an SVR is identical (RR 1. The trials included in this review are also characterized by frequent methodological shortcomings.
Fluoxetine cheap dipyridamole 25 mg amex pulse pressure variation, cognitive-behavioral therapy generic dipyridamole 100mg with mastercard prehypertension 2016, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Suicidal events in the Treatment for Adolescents with Depression Study (TADS). Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. Second-generation antidepressants 126 of 190 Final Update 5 Report Drug Effectiveness Review Project 155. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Justin C, Burt T. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A doubleblind switch study of paroxetine and venlafaxine in obsessivecompulsive disorder. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Second-generation antidepressants 127 of 190 Final Update 5 Report Drug Effectiveness Review Project 169. Efficacy of drug treatment in obsessive-compulsive disorder. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.
Concurrent expression of cancer by inhibiting BET bromodomains buy generic dipyridamole 25 mg online heart attack feat mike mccready amp money mark. MYC and BCL2 in diffuse large B-cell lymphoma treated with 2011;108(40):16669-16674 discount 100mg dipyridamole with visa prehypertension prevalence. Gerds1 1Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH The myelodysplastic syndromes (MDS) are the most commonly diagnosed myeloid malignancy, with 15 000 new cases identiﬁed in the United States yearly. Prognostic scoring systems supplant a formal staging approach and, in general, divide patients into those with lower-risk and those with higher-risk MDS. Although treatment goals for patients with lower-risk disease focus on minimizing transfusions and optimizing quality of life, in higher-risk MDS, the goal is to delay transformation to acute leukemia and to prolong survival. In lower-risk patients, isolated cytopenias are treated with erythropoiesis-stimulating agents or growth factors such as thrombopoietin mimetics. For patients with the del(5q) cytogenetic abnormality or those who fail these initial approaches, lenalidomide may be tried, as can experimental agents. Lower-risk patients with multiple cytopenias may be treated with immunosuppressive drugs or low-dose hypomethylating agents. For patients with higher-risk disease, hypomethylating agents are the preferred initial treatment approach, with evaluation for hematopoietic cell transplantation at diagnosis. Several novel agents are being developed for MDS patients who have failed hypomethylating drugs. They are the most commonly diagnosed myeloid neoplasms in treatment is to make sure that the patient understands the severity of the United States, with an incidence rate of 4. This ﬁgure derives from the National Cancer Institute’s Surveillance, Epidemiology, statement, treatment goals for patients with lower-risk disease focus and End Results program and the North American Association of on minimizing transfusions and optimizing quality of life. Because Central Cancer Registries and is considered a substantial underesti- no therapy for lower-risk disease has been shown prospectively to mate, because it is likely compromised by misclassiﬁcation (50% of improve overall survival, in asymptomatic patients with relatively patients in such registries, a proportion much higher than the preserved blood counts, treatment initiation should be delayed as expected rate, are identiﬁed as “MDS–unclassiﬁable”) and underre- long as possible. In contrast, for higher-risk patients, in whom porting (because the assumption often is made that cytopenias in survival is severely truncated and transformation to acute myeloid 2 leukemia (AML) is likely and akin to a death knell,3,6 treatment older adults are a natural, nonmalignant consequence of aging). Treatment decisions in MDS depend largely on pathology or prognostic scoring systems appropriated as default staging sys- 3 Therapies for lower-risk MDS tems. These prognostic systems, the most widely used being the International Prognostic Scoring System (IPSS), are based most Initial treatment of isolated cytopenias commonly on blast percentage, cytogenetic risk groups, and cytope- Most lower-risk MDS patients initiate their diagnostic evaluation as nias, and may also include age, performance status, transfusion a result of cytopenias detected on routine blood work, the most needs, and other clinical (and increasingly molecular) factors. Therefore, therapies focus on alleviat- simpler approach is to divide patients into those with lower-risk or ing those cytopenias (Figure 1). This is initially accomplished most higher-risk disease. Patients with lower-risk MDS fall into IPSS easily through transfusions (for anemia or thrombocytopenia) or categories of low and intermediate-1, corresponding largely to through the use of erythropoiesis-stimulating agents (ESAs) or revised IPSS (IPSS-R) groups very low, low, and sometimes growth factors. For these patients, median overall survival logic improvement to ESAs for a median duration of 2 years. Patients with higher-risk disease fall into model developed by the Nordic MDS group identiﬁes patients more IPSS categories of intermediate-2 and high groups, corresponding likely to respond to ESAs. Those with low or absent transfusion 82 American Society of Hematology Figure 1. Food and Drug Administra- etin levels ( 500 units, or 7%). Its activity improved quality of life if treated initially with ESAs, whereas those is thought to be mediated through selective suppression of del(5q) in the latter group have improved outcomes if treated initially with clones by inhibition of haplodeﬁcient phosphatases encoded within non-growth-factor approaches. The largest study In the phase 2 registration study conducted in del(5q) patients,20 148 randomized 250 lower-risk MDS patients with thrombocytopenia in were treated with lenalidomide, of whom 99 (67%) achieved a 2:1 fashion to receive romiplostim or placebo. The number of transfusion independence, including every patient who experienced clinically signiﬁcant bleeding events favored patients receiving a cytogenetic response. A subsequent phase 3, double-blind trial of lenalidomide conclusions based on baseline platelet transfusion needs and serum at 2 different doses versus supportive care in a similar population thrombopoietin levels. The study was stopped early due to concern demonstrated transfusion independence responses lasting 6 months by the data monitoring committee of an increased rate of AML in 43%–52% of subjects, compared with 6% of controls, and a evolution and an increase in myeloblasts seen in the romiplostim cytogenetic response rate in lenalidomide-treated subjects of 25%– group [hazard ratio (HR) 2. Given these concerns, the use of independence and reduced risk of AML transformation or death, either romiplostim or eltrombopag should be avoided in patients whereas treatment-related thrombocytopenia has been associated with excess blasts. Presumptive use of granulocyte (or granulocyte macrophage) colony In anemic, lower-risk MDS patients who do not harbor the stimulating factors for MDS patients with neutropenia has never del(5q) lesion, a phase 2 study of lenalidomide similar in design been shown prospectively to reduce episodes of febrile neutropenia to the registration study enrolled 215 patients. Novel agents and combinations for MDS Agent(s) Mechanism of action Development stage Comments Lower-risk MDS Romiplostim Thrombopoietin receptor agonist Randomized phase 2 trial Romiplostim improved clinically signiﬁcant (N 250) bleeding events and IWG platelet response rates; increase in myeloblasts in patients with baseline excess blasts. Eltrombopag Thrombopoietin receptor agonist Randomized phase 2 trial Eltrombopag improved platelet counts (still enrolling, N 17/171 and quality of life (preliminary).
9 of 10 - Review by O. Deckard
Votes: 287 votes
Total customer reviews: 287